Angelini Labopharm LLC
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Angelini Labopharm LLC
With China CNS Plans, SK Biopharm Completes Strategy For Key Markets
SK Biopharmaceuticals advances into the Greater China market via a CNS focused Chinese company with China’s 6 Dimensions Capital, backed by a large series A financing. It has also licensed its CNS therapy pipeline to the new Chinese operation.
Korea Q2 Roundup: Mixed Bag As Pandemic Buoys Some, Hits Others
Two SK Group affiliates benefit from COVID-19 vaccine manufacturing activities and US sales of novel drugs, while other factors such as a recovery in prescription sales, new launches and falling milestone payments affected results at other traditional South Korean pharma firms in the second quarter.
Ovid Shifts Focus After Angelman Syndrome Drug Disappoints In Phase III
The Phase III clinical trial showed a noticeable placebo effect compared with OV101.
Takeda/Ovid Plan Phase III For Soticlestat In Dravet Syndrome, But Pull Back On LGS
A Phase II trial of the CH24H inhibitor showed a statistically significant benefit in children with the rare epilepsy syndrome Dravet Syndrome, but not in Lennox-Gastaut syndrome (LGS).
Company Information
- Industry
- Pharmaceuticals